U.S. Markets closed

BioDelivery Sciences International, Inc. (BDSI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3800+0.2050 (+6.46%)
At close: 4:00PM EDT

BioDelivery Sciences International, Inc.

4131 ParkLake Avenue
Suite 225
Raleigh, NC 27612
United States
919 582 9050
http://www.bdsi.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees176

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey Allen BaileyCEO & Director599.96kN/A1963
Mr. Scott M. PleshaPres & Chief Commercial Officer629.46kN/A1965
Ms. Mary Theresa CoelhoExec. VP, CFO & Treasurer657.17k74.98k1963
Mr. James Vollins J.D.Gen. Counsel, Chief Compliance Officer & Corp. Sec.586.68k45.09k1969
Dr. Thomas B. Smith FAAFP, M.D.Chief Medical Officer570.06kN/A1961
Mr. Joseph M. LockhartSr. VP of OperationsN/AN/AN/A
Mr. Kevin OstranderSr. VP of Bus. Devel.N/AN/AN/A
Dr. Bill McCarbergMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardN/AN/AN/A
Dr. Arthur G. Lipman PharmDMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardN/AN/AN/A
Dr. Jeff KatzMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.

Corporate Governance

BioDelivery Sciences International, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.